Product Information
Registration Status: ActiveSIN12345P
MEN'S REGAINE REGULAR STRENGTH (2%) is approved to be sold in Singapore with effective from 2003-10-07. It is marketed by JOHNSON & JOHNSON PTE LTD, with the registration number of SIN12345P.
This product contains Minoxidil 2% w/v in the form of SOLUTION. It is approved for TOPICAL use.
This product is manufactured by PFIZER MANUFACTURING BELGIUM NV in UNITED STATES, andPharmacia and Upjohn Company in BELGIUM.
It is an Over-the-counter Medicine that can be freely obtained from any retailer
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
Indication
For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.
Mechanism of Action
Minoxidil is thought to promote the survival of human dermal papillary cells (DPCs) or hair cells by activating both extracellular signal-regulated kinase (ERK) and Akt and by preventing cell death by increasing the ratio of BCl-2/Bax. Minoxidil may stimulate the growth of human hairs by prolonging anagen through these proliferative and anti-apoptotic effects on DPCs. Minoxidil, when used as a vasodilator, acts by opening adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells. This vasodilation may also improve the viability of hair cells or hair follicles.
Pharmacokinetics
- Absorption
- Minoxidil is at least 90% absorbed from the GI tract in experimental animals and man.
- Distribution
- Metabolism
- Approximately 90% of the administered drug is metabolized, predominantly by conjugation with glucuronic acid at the N-oxide position in the pyrimidine ring, but also by conversion to more polar products. Known metabolites exert much less pharmacologic effect than minoxidil itself.
- Elimination
Toxicity
Oral LD50 in rats has ranged from 1321-3492 mg/kg; in mice, 2456-2648 mg/kg. Side effects include cardiovascular effects associated with hypotension such as sudden weight gain, rapid heart beat, faintness or dizziness.
Active Ingredient/Synonyms
2,4-Diamino-6-piperidinopyrimidine 3-oxide | 6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide | Alostil | Apo-gain | Lonolox | Minossidile | Minoxidil | Minoxidilum | Minoximen | Normoxidil | Regaine | Tricoxidil | Minoxidil |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.